Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine Betuvax-CoV-2
Clinical trial NCT05270954 · UNKNOWN
Trial details
- NCT number
- NCT05270954
- Sponsor
- Artgen Biotech
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-14
- Primary completion
- 2022-04-25
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.